You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ):合作研發的新冠病毒mRNA疫苗獲尼泊爾Ⅲ期臨牀試驗批件
格隆匯 09-22 16:07

格隆匯9月22日丨沃森生物(300142.SZ)公佈,公司與蘇州艾博生物科技有限公司合作研發的新型冠狀病毒 mRNA 疫苗於近日獲得了尼泊爾藥監部門頒發的Ⅲ期臨牀試驗批件,標誌着新型冠狀病毒 mRNA 疫苗在尼泊爾進入Ⅲ期臨牀試驗階段。

該疫苗用於預防由SARS-CoV-2感染所致的疾病(COVID-19)。該疫苗的研究獲得了國家科技部重點研發計劃“公共安全風險防控與應急技術裝備”重點專項支持,為科技部部署的新冠疫苗5條技術路線中的“核酸疫苗”技術路線。該疫苗是中國首個獲批進入臨牀試驗階段的新型冠狀病毒mRNA疫苗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account